We next subclassified patients with COVID-19 and controls based on the presence or absence of spike-specific IgG and/or IgA in the plasma (P) or nasopharynx (N) as type A (PN+; 29.3%), type B (P+; 36.5%), type C (N+; 4.9%) or type D (PN−; 29.3%) responders (Fig. 2e,f and Extended Data Fig. 2e). Here, CD79A is linked to COVID-19.